Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control

@article{Janavicius2010FounderBM,
  title={Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control},
  author={Ramunas Janavicius},
  journal={The EPMA Journal},
  year={2010},
  volume={1},
  pages={397 - 412}
}
  • R. Janavicius
  • Published 27 June 2010
  • Medicine, Biology
  • The EPMA Journal
Detection of mutations in hereditary breast and ovarian cancer-related BRCA1 and BRCA2 genes is an effective method of cancer prevention and early detection. Different ethnic and geographical regions have different BRCA1 and BRCA2 mutation spectrum and prevalence. Along with the emerging targeted therapy, demand and uptake for rapid BRCA1/2 mutations testing will increase in a near future. However, current patients selection and genetic testing strategies in most countries impose significant… 

Tables from this paper

Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC)
TLDR
A study in which BRCA1/2 punctual variants and copy number variations are analyzed on selected Moroccan patients suspected of having HBOC syndrome to report four pathogenic variants that to the best of the authors' knowledge has never been reported in the Moroccan population before.
Hereditary breast cancer in South-Eastern Norway BRCA1/2- testing of breast cancer patients. Mutation spectrum and potential modifiers in Norwegian BRCA1/2 carriers
TLDR
It is suggested it is time to discuss whether all BC patients should be offered BRCA testing, both to optimize treatment and improve survival for these women, but also to enable identification of healthy mutation carriers within their families.
Spectrum of Germline Pathogenic Variants in BRCA1/2 Genes in the Apulian Southern Italy Population: Geographic Distribution and Evidence for Targeted Genetic Testing
TLDR
It is found that ten recurrent BRCA1/2 pathogenic variants account for more than half of the patients with proven HBOC syndrome from Apulia, the first study that exclusively focused on native Apulian probands.
Erratum to: Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history
TLDR
The data suggests that panel testing may help to identify carriers, particularly Asian BRCA2 carriers, who do not present with a priori strong family history characteristics.
Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
TLDR
It is shown that targeting relevant exons in BRCA1 and BRCa2 genes allows detection of a substantial percentage of mutations in the Tunisian population.
Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels
TLDR
The developed genotyping panel showed to be an easy-to-perform and more affordable testing tool that can provide important contributions to improve the healthcare of Chinese women with cancer as well as family members that harbor high risk mutations for HBOC.
Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients
TLDR
The prioritization of BRCA1- c.211dupA screening in high risk breast cancer families originating from the North-East of Tunisia is recommended and the importance of NGS in detecting novel mutations, such as RAD50-c.3647C > G on RAD50, is highlighted.
Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history
TLDR
The data suggests that panel testing may help to identify carriers, particularly Asian BRCA2 carriers, who do not present with a priori strong family history characteristics.
The Potential Contribution of BRCA Mutations to Early Onset and Familial Breast Cancer in Uzbekistan
TLDR
Taking into account a high disease penetrance in carriers of BRCA1 mutation, it seems reasonable to recommend inclusion of the 5382insC mutation test in future research on the development of screening programs for breast cancer prevention in Uzbekistan.
BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway
TLDR
The spectrum of B RCA1 and BRCA2 mutations in the carrier population at Norway’s largest cancer genetics clinic is diverse, and with a weaker founder effect than previously described.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 187 REFERENCES
BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses
TLDR
The present study is the first BRCA1 disease-associated mutations analysis in Southern Italian families and identified a BRCa1 mutation with a possible founder effect.
Two founder BRCA2 mutations predispose to breast cancer in young women
TLDR
The identification of founder effects improves the genetic screening strategy to be followed and facilitates the clinical management of asymptomatic carriers.
A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques
TLDR
It is shown that the founder mutation BRCA1 c.3171ins5 has a great influence on western Swedish breast/ovarian cancer families along with a high number of mutations unique for the region.
Founder mutations in BRCA1 and BRCA2 genes.
  • R. Ferla, V. Caló, A. Russo
  • Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
TLDR
The identification of the ethnic group of families undergoing genetic counseling enables the geneticist and oncologist to make more specific choices, leading to simplify the clinical approach to genetic testing carried out on members of high-risk families.
Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients
TLDR
A hierarchical, cost-effective BRCA1/2 mutation screening protocol for individuals of Greek ethnic origin is proposed and can impact on the clinical management of breast-ovarian cancer families on a national healthcare system level.
Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer
TLDR
An evaluation of deleterious genetic variants in the BRCA1 and 2 genes in the Czech population and the classification of several splice-site variants as true pathogenic mutations may prove useful for genetic counselling of families with high risk of breast and ovarian cancer.
Genetic and Preventive Services for Hereditary Breast and Ovarian Cancer in the Czech Republic
TLDR
The testing of BRCA1/BRCA2 or other possible predisposition genes for hereditary breast/ovarian cancer is determined by medical geneticists after genetic counselling and predictive testing is offered to persons older than 18 years of age.
Founder mutations in the BRCA1 gene in west Belarusian breast‐ovarian cancer families
TLDR
A hospital-based study to identify possible BRCA1 mutations in the west Belarusian population and evaluated a panel of 19 Belarusian families with aggregation of breast and ovarian cancers for occurrence of five BRCa1 constitutional mutations found recently to be recurrent in the Polish population.
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects
TLDR
A higher frequency of ovarian cancer associated with mutations localized in the 5′ end of the BRCA1 gene is found, but there was no association between the prevalence of this type of cancer and mutations situated in the ovarian cancer cluster region (OCCR).
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
TLDR
Estimates of penetrance (cancer risk) vary considerably depending on the context in which they were derived and have been shown to vary within families with the same BRCA1/2 mutation, suggesting there is no exact risk estimate that can be applied to all individuals with a BRCa1/ 2 mutation.
...
1
2
3
4
5
...